MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/25787489.2025.2456890

Медицинская библиотека · HIV research & clinical practice · 2025

Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort.

Trottier Benoit, Yang Chia-Jui, Watanabe Dai, Marchetti Giulia, Elbirt Daniel, De Barra Eoghan, Gündüz Alper, Lee Sun Hee, Vogelmann Roger, Robineau Olivier, Choy Chiaw Yee, Berrevoets Marvin, Uriel Alison, Thorpe David, Heinzkill Marion, Marongiu Andrea, Ramroth Johanna, D'Amato Lisa, Mallolas Josep

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

BICtegravir Single Tablet Regimen (BICSTaR) is an observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV.

OBJECTIVE

To present final pooled 24-month outcomes for the full cohort.

METHODS

Prospective data were pooled from TN and TE adults with HIV initiating B/F/TAF in routine clinical practice across 14 countries (data collection: 25/06/2018-29/12/2023). Outcomes at 24 months included virologic suppression (HIV-1 RNA <50 copies/mL), immunologic effectiveness (change in CD4 cell count and CD4/CD8 ratio), persistence, and safety. Outcomes were also analysed in key populations.

RESULTS

Of 2,074 (483 TN, 1,591 TE) participants included, most were male (85%), White (70%), and had ≥1 comorbidity (66%). Median (Q1, Q3) age was 45 (35, 54) years. At 24 months, 94% of TN and 96% of TE participants had HIV-1 RNA <50 copies/mL (missing = excluded analysis). These values were 88% and 86%, respectively, in a discontinuation = failure analysis. Effectiveness remained high across all key populations at 24 months. Median (Q1, Q3) CD4 count increased by 257 (127, 447) cells/µL in TN and 40 (-70, 153) cells/µL in TE participants (both p < 0.001). There was no reported treatment-emergent resistance to B/F/TAF. Persistence was high at 24 months (TN, 95%; TE, 91%). Drug-related adverse events occurred in 11% of TN and 12% of TE participants, leading to B/F/TAF discontinuation in 5%.

CONCLUSIONS

B/F/TAF was generally well tolerated over 24 months, with high effectiveness and persistence observed among a broad range of people with HIV.

Для цитирования: Trottier Benoit, Yang Chia-Jui, Watanabe Dai, Marchetti Giulia, Elbirt Daniel, De Barra Eoghan, Gündüz Alper, Lee Sun Hee, Vogelmann Roger, Robineau Olivier, Choy Chiaw Yee, Berrevoets Marvin, Uriel Alison, Thorpe David, Heinzkill Marion, Marongiu Andrea, Ramroth Johanna, D'Amato Lisa, Mallolas Josep. Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort.. HIV research & clinical practice. 2025. DOI: 10.1080/25787489.2025.2456890.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.